-
1
-
-
26044461277
-
Endocannabinoids in the regulation of appetite and body weight
-
Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav. Pharmacol. 16 (2005) 297-313
-
(2005)
Behav. Pharmacol.
, vol.16
, pp. 297-313
-
-
Kirkham, T.C.1
-
2
-
-
0028129936
-
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
-
Rinaldi-Carmona M., Barth F., Heaulme M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
-
(1994)
FEBS Lett.
, vol.350
, pp. 240-244
-
-
Rinaldi-Carmona, M.1
Barth, F.2
Heaulme, M.3
-
3
-
-
0030853692
-
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor
-
Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., and Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334 (1997) R1-R2
-
(1997)
Eur. J. Pharmacol.
, vol.334
-
-
Landsman, R.S.1
Burkey, T.H.2
Consroe, P.3
Roeske, W.R.4
Yamamura, H.I.5
-
4
-
-
0030738512
-
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
-
Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., and Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berlin) 132 (1997) 104-106
-
(1997)
Psychopharmacology (Berlin)
, vol.132
, pp. 104-106
-
-
Arnone, M.1
Maruani, J.2
Chaperon, F.3
Thiebot, M.H.4
Poncelet, M.5
Soubrie, P.6
Le Fur, G.7
-
5
-
-
32644441249
-
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
-
Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
-
(2006)
JAMA
, vol.295
, pp. 761-775
-
-
Pi-Sunyer, F.X.1
Aronne, L.J.2
Heshmati, H.M.3
Devin, J.4
Rosenstock, J.5
-
6
-
-
17144382751
-
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
-
Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
-
(2005)
Lancet
, vol.365
, pp. 1389-1397
-
-
Van Gaal, L.F.1
Rissanen, A.M.2
Scheen, A.J.3
Ziegler, O.4
Rossner, S.5
-
7
-
-
33751001942
-
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
-
Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
-
(2006)
Lancet
, vol.368
, pp. 1660-1672
-
-
Scheen, A.J.1
Finer, N.2
Hollander, P.3
Jensen, M.D.4
Van Gaal, L.F.5
-
8
-
-
27844463517
-
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
-
Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 2121-2134
-
-
Despres, J.P.1
Golay, A.2
Sjostrom, L.3
-
9
-
-
34249849860
-
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data
-
Bronander K.A., and Bloch M.J. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vasc. Health Risk Manage. 3 (2007) 181-190
-
(2007)
Vasc. Health Risk Manage.
, vol.3
, pp. 181-190
-
-
Bronander, K.A.1
Bloch, M.J.2
-
10
-
-
60549088559
-
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-Yl]-4-ethylaminopiperidine-4-carboxylic acid amine hydrochloride (CP-945,598), a novel, potent and selective cannabinoid CB1 receptor antagonist
-
Griffith D.A., Hadcock J.R., Black S.C., et al. Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-Yl]-4-ethylaminopiperidine-4-carboxylic acid amine hydrochloride (CP-945,598), a novel, potent and selective cannabinoid CB1 receptor antagonist. J. Med. Chem. 52 (2009) 234-237
-
(2009)
J. Med. Chem.
, vol.52
, pp. 234-237
-
-
Griffith, D.A.1
Hadcock, J.R.2
Black, S.C.3
-
11
-
-
0029859983
-
Identification and characterization of novel somatostatin antagonists
-
Bass R.T., Buckwalter B.L., Patel B.P., et al. Identification and characterization of novel somatostatin antagonists. Mol. Pharmacol. 50 (1996) 709-715
-
(1996)
Mol. Pharmacol.
, vol.50
, pp. 709-715
-
-
Bass, R.T.1
Buckwalter, B.L.2
Patel, B.P.3
-
12
-
-
77950188073
-
1 receptor antagonists in a drug development program for weight loss management
-
submitted for publication
-
1 receptor antagonists in a drug development program for weight loss management, Clin. Pharmacol. Ther., submitted for publication.
-
Clin. Pharmacol. Ther
-
-
Scott, D.O.1
Griffith, D.A.2
Iredale, P.A.3
Carpino, P.A.4
Dow, R.L.5
Black, S.C.6
Kelly-Sullivan, D.M.7
Tess, D.8
Hadcock, S.M.J.R.9
-
15
-
-
0031032872
-
SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
-
Richardson J.D., Aanonsen L., and Hargreaves K.M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319 (1997) R3-R4
-
(1997)
Eur. J. Pharmacol.
, vol.319
-
-
Richardson, J.D.1
Aanonsen, L.2
Hargreaves, K.M.3
-
16
-
-
0024268922
-
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice
-
Little P.J., Compton D.R., Johnson M.R., Melvin L.S., and Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247 (1988) 1046-1051
-
(1988)
J. Pharmacol. Exp. Ther.
, vol.247
, pp. 1046-1051
-
-
Little, P.J.1
Compton, D.R.2
Johnson, M.R.3
Melvin, L.S.4
Martin, B.R.5
-
17
-
-
18444376760
-
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
-
Howlett A.C., Barth F., Bonner T.I., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
-
(2002)
Pharmacol. Rev.
, vol.54
, pp. 161-202
-
-
Howlett, A.C.1
Barth, F.2
Bonner, T.I.3
-
18
-
-
0023474376
-
Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids
-
Martin B.R., Compton D.R., Little P.J., Martin T.J., and Beardsley P.M. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. NIDA Res. Monogr. 79 (1987) 108-122
-
(1987)
NIDA Res. Monogr.
, vol.79
, pp. 108-122
-
-
Martin, B.R.1
Compton, D.R.2
Little, P.J.3
Martin, T.J.4
Beardsley, P.M.5
-
19
-
-
23044447712
-
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice
-
Varvel S.A., Bridgen D.T., Tao Q., Thomas B.F., Martin B.R., and Lichtman A.H. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J. Pharmacol. Exp. Ther. 314 (2005) 329-337
-
(2005)
J. Pharmacol. Exp. Ther.
, vol.314
, pp. 329-337
-
-
Varvel, S.A.1
Bridgen, D.T.2
Tao, Q.3
Thomas, B.F.4
Martin, B.R.5
Lichtman, A.H.6
-
20
-
-
0032541111
-
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
-
Colombo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63 (1998) PL113-PL117
-
(1998)
Life Sci.
, vol.63
-
-
Colombo, G.1
Agabio, R.2
Diaz, G.3
Lobina, C.4
Reali, R.5
Gessa, G.L.6
-
21
-
-
0038070321
-
Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats
-
Vickers S.P., Webster L.J., Wyatt A., Dourish C.T., and Kennett G.A. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berlin) 167 (2003) 103-111
-
(2003)
Psychopharmacology (Berlin)
, vol.167
, pp. 103-111
-
-
Vickers, S.P.1
Webster, L.J.2
Wyatt, A.3
Dourish, C.T.4
Kennett, G.A.5
-
22
-
-
34249097103
-
Role of cannabinoid CB2 receptors in glucose homeostasis in rats
-
Bermudez-Silva F.J., Sanchez-Vera I., Suarez J., et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur. J. Pharmacol. 565 (2007) 207-211
-
(2007)
Eur. J. Pharmacol.
, vol.565
, pp. 207-211
-
-
Bermudez-Silva, F.J.1
Sanchez-Vera, I.2
Suarez, J.3
-
23
-
-
13244249625
-
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice
-
Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. (Lond.) 29 (2005) 183-187
-
(2005)
Int. J. Obes. (Lond.)
, vol.29
, pp. 183-187
-
-
Liu, Y.L.1
Connoley, I.P.2
Wilson, C.A.3
Stock, M.J.4
|